Abstract 139P
Background
Rearranged during transfection (RET) rearrangement is detected in 1% to 2% of non-small cell lung cancer (NSCLC), and RET rearrangement have been characterized most extensively in colorectal cancer and papillary thyroid carcinomas, and also have been observed in other cancers. More than 30 different fusion partner genes of RET have been reported and some of the RET fusions respond well to cabozantinib and vandetanib. With the development of next-generation sequencing (NGS), more novel partners for RET rearrangement have been identified. Here, we aimed to report the landscape of RET rearrangement in Chinese patients with solid tumors.
Methods
Tissue or blood samples were subjected to NGS in a College of American Pathologists-certified and Clinical Laboratory Improvement Amendments-accredited lab for RET arrangement.
Results
In total, we profiled more than 40,000 patients, among which 237 cases with 29 RET fusion partner, harboring 13 reported partners and 16 novel partners. The average RET rearrangement patients' age was 58 years (range, 23-91 years). Among all the RET fusion cases (n=237), lung cancer were the largest proportion with 88.6% (n=210), colorectal cancer accounted for 5.5% (n=13), thyroid cancer and breast cancer accounted for 1.3% (n=3) respectively. And liver cancer and pancreatic cancer accounted for 0.8% (n=2) respectively, and only one case (n=1) was accounted ncancer, gastric cancer, ovarian cancer and sarcoma. The most common reported RET fusion partners were KIF5B (n=157), CCDC6 (n=41) and NCOA4 (n=15). In 24 cases, 14 novel RET fusion partners were discovered, the highest frequency novel partner is TIMM23B (n=11). Moreover all the fusion TIMM23B –RET are coupled with the fusion NCOA4-RET in 11 patients, which were four lung cancer patients, six colorectal cancer patients and one liver cancer patient. There was a special lung cancer cases with three RET fusions (ANKRD26-RET, KIAA1217-RET, MBIP-RET).
Conclusions
Novel RET fusions are detected in patients with not only NSCLC but also other solid tumors. NGS fusion assay is an optional method for screening novel fusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.